U.S. Diversified Financial Stock News

Context for Globant’s recent share performance Globant (GLOB) has moved quietly on relatively mixed recent returns, combining a modest daily gain with weaker month performance and stronger past 3 months momentum, which puts its current valuation and fundamentals in sharper focus for investors. See our latest analysis for Globant. At around $68.20, Globant’s recent 1 day share price return of 1.07% sits against a weaker 30 day share price return of 1.84% and a stronger 90 day share price...

In mid-January 2026, The J.M. Smucker Co. announced its Board approved a US$1.10 per share quarterly dividend, payable on March 2, 2026, to shareholders of record as of February 13, reinforcing its ongoing capital return to investors. Around the same time, Morgan Stanley cut its rating on J.M. Smucker to Equal Weight, underscoring concerns about rising competitive pressures and valuation risks despite the steady dividend payout. With Morgan Stanley flagging increased competitive risk, we’ll...

Legend Biotech (LEGN) used its recent J.P. Morgan conference update to spotlight revenue growth, margin progress and an outlook for profitability in 2026, anchored by its multiple myeloma therapy CARVYKTI and partnership with Johnson & Johnson. See our latest analysis for Legend Biotech. Legend Biotech’s recent conference update comes after a tough run for investors, with a 90 day share price return of a 32.73% decline and a 1 year total shareholder return of a 32.21% decline, while the 30...

V2X (VVX) has been drawing fresh attention after securing a place on the Missile Defense Agency’s SHIELD IDIQ contract vehicle, a US$151.0b ceiling program tied to the Golden Dome American defense modernization effort. See our latest analysis for V2X. The SHIELD award and recent board appointments come at a time when momentum in V2X’s shares has picked up, with a 27.11% 1 month share price return and a 28.43% 1 year total shareholder return suggesting building interest around its defense...

Venture Global (VG) is back on investor radars after a recent price move, with the stock up 10.6% over the past day and 21.7% across the past week, outpacing its performance over the past month. See our latest analysis for Venture Global. The sharp 1 day share price return of 10.55% and 7 day share price return of 21.72% comes after a mixed few months, with a 30 day share price return of 38.58% contrasting with a 90 day share price decline of 5.27%. Recent momentum appears stronger when...

Minerals Technologies (MTX) has put its paper and packaging business in Asia firmly in focus, with three new satellite plants starting in 2025, a capacity doubling in India, and another plant planned in China for early 2026. See our latest analysis for Minerals Technologies. The expansion news comes as Minerals Technologies' share price has climbed 10.9% over the past month and 10.4% over the past quarter. However, the 1 year total shareholder return of an 11.2% decline and the low single...

BXP recently announced that Starr, a global investment and insurance organization, signed a 20-year lease for approximately 275,000 square feet, about 30% of the space, at 343 Madison Avenue, a 930,000 square foot, fully electric tower in Midtown Manhattan that BXP expects to deliver in late 2029. The long-term, headquarters lease with an investment-grade tenant at 343 Madison Avenue highlights early pre-leasing momentum and helps underpin BXP's large, sustainability-focused development,...

In December, Immunome, Inc. reported positive topline results from its Phase 3 RINGSIDE trial, showing Varegacestat improved progression-free survival versus placebo and plans to seek FDA approval in the second quarter of 2026. The data, including a marked reduction in the risk of death or disease progression and a high rate of tumor shrinkage, positions Varegacestat as a potentially important addition to Immunome’s oncology pipeline. Next, we’ll examine how Varegacestat’s strong Phase 3...

Fortrea Holdings (FTRE) saw its shares climb 4.8% after Evercore ISI upgraded the stock, citing stronger than expected revenue and profit margins, progress on debt reduction, and a quickening biopharma cycle. See our latest analysis for Fortrea Holdings. Even after the upgrade driven jump, Fortrea’s recent trading has been choppy. The 1 day share price return of 3.38% contrasts with 7 day and 30 day share price returns of 5.12% and 6.99% declines. A 90 day share price return of 58.35% hints...

What the recent return profile says about Post Holdings stock Post Holdings (POST) shares have tracked a mixed path recently, with a 1 day gain of about 1.3%, modest movement over the past week, and declines over the month and past 3 months. Over longer periods, the picture shifts, with negative total return over the past year but positive outcomes over 3 and 5 years. This can matter if you are thinking about holding the stock through different market cycles. Alongside that performance...

IDEAYA Biosciences (IDYA) is back in focus after a cluster of upbeat analyst reports highlighted its precision oncology pipeline and its partnerships with GlaxoSmithKline, Pfizer, and Gilead, drawing fresh attention to the stock. See our latest analysis for IDEAYA Biosciences. After a strong run that leaves the 1 year total shareholder return at 61.59% and the 3 year total shareholder return just over double, recent 7 day and 1 day share price weakness sits against a 90 day share price return...

Recently published government-funded research has challenged the scientific basis of existing US cannabis DUI laws, arguing they often penalize drivers without clear evidence of impairment and may be leading to wrongful incarceration. This push to modernize THC intoxication standards could ease regulatory frictions for the legal cannabis ecosystem, indirectly supporting ancillary players such as cannabis-focused landlord Innovative Industrial Properties. We’ll now consider how fresh scrutiny...

Prosperity Bancshares (PB) has been drawing attention after recent share price moves, with the stock closing at US$72.39 and showing mixed returns over the past year and the past 3 months. See our latest analysis for Prosperity Bancshares. The recent pullback in the 1-day share price return of 1% comes after a stronger 90-day share price return of 13.09%. At the same time, the 1-year total shareholder return shows a decline of 5.08%, indicating that longer term results have been more muted...

Asthma data and 2026 pipeline milestones come into focus Apogee Therapeutics (APGE) attracted fresh attention after reporting positive interim Phase 1b data for zumilokibart in mild to moderate asthma, alongside outlining key 2026 milestones across atopic dermatitis and other inflammatory indications. See our latest analysis for Apogee Therapeutics. Against this backdrop, Apogee’s recent asthma update and 2026 pipeline timeline arrive after a strong 90 day share price return of 41.85% and a 1...

UFP Technologies (UFPT) has drawn attention after recent share price moves, with the stock showing double digit returns over the past month and over the past 3 months, in contrast with a slightly negative 1 year total return. See our latest analysis for UFP Technologies. At a share price of $260.52, UFP Technologies has seen short term momentum build, with double digit 30 day and 90 day share price returns. This is occurring even though the 1 year total shareholder return is slightly...

Mercury Systems, Inc. recently announced contract awards totaling more than US$60 million for two critical U.S. space and strategic weapons programs, including a development contract extension on a large strategic weapons effort running through 2031 and a new award to supply radiation-tolerant subsystems for a national security space mission. The wins highlight growing customer adoption of Mercury’s radiation-hardened and radiation-tolerant processing technologies, including subsystems built...

In the recent quarter, Core & Main reported revenue growth of 1.2% year on year and delivered adjusted operating income above analyst expectations, signaling resilient demand across its water infrastructure distribution business. This earnings performance highlights how Core & Main’s focus on supply chain and inventory management is becoming a central driver of its operational strength within industrial distribution. With this earnings beat underscoring operational execution, we’ll now...

Earlier this month, KB Home announced the grand openings of its Meridian and Solstice communities in Ontario and the Somerset community in Victorville, expanding its presence in Southern California with ENERGY STAR®-designed, highly customizable homes and family-focused amenities. These launches highlight KB Home’s emphasis on personalized design, energy and water efficiency, and master-planned community living, reinforcing its customer-satisfaction positioning as a #1 national homebuilder...

Kodiak Gas Services (KGS) is back in focus after a cluster of analyst upgrades and fresh research pointing to firm demand for its gas compression services, tight equipment supply, and solid execution. See our latest analysis for Kodiak Gas Services. At a share price of $37.73, Kodiak Gas Services has posted a 7.04% 90 day share price return, while its 1 year total shareholder return of 16.31% decline shows that recent momentum has picked up after a weaker year, likely helped by the analyst...

Moog Inc. recently presented at CJS Securities’ 26th Annual “New Ideas for the New Year” Investor Conference on January 14, 2026, featuring Executive VP & CFO Jennifer Walter and President, CEO & Director Patrick J. Roche outlining the company’s current positioning and outlook. At the same time, analysts’ more cautious earnings forecasts ahead of Moog’s upcoming December 2025-quarter results have introduced fresh uncertainty around a company that had previously been consistently ahead of...

Event context and immediate market snapshot eToro Group (ETOR) is drawing fresh attention after recent trading performance, with the share price closing at $31.33 and short term returns showing a mix of small daily moves and weaker month and past 3 months performance. For investors watching entry points, this recent stretch includes a 1 day return of 0.19%, along with negative moves of 0.92% over the past week, 13.48% over the past month, and 20.80% over the past 3 months. See our latest...

In recent days, Hub Group has drawn renewed attention after several major research firms upgraded their views or reaffirmed positive ratings, citing expectations of improving intermodal volumes, resilient cash generation, and benefits from ongoing tuck-in acquisitions across brokerage, last‑mile, and dedicated services. A key twist is Evercore ISI’s view that Hub Group could be a prime beneficiary of the proposed Union Pacific–Norfolk Southern merger, given its scale as an asset-based...

If you are asking yourself whether Amicus Therapeutics at around US$14.33 offers good value, you are not alone. This article is designed to help you think that through clearly. The stock has returned 0.4% over the last 7 days, 1.1% over the past month, 0.4% year to date, and 52.3% over the last year, which can influence how you think about both its growth potential and its current risk profile. Recent coverage of Amicus Therapeutics has focused on its position as a rare disease drug...

If you are wondering whether Under Armour’s current share price offers a genuine bargain or just appears cheap on the surface, this article is designed to walk you through the key valuation angles to consider. The stock last closed at US$5.78, with returns of 2.5% over 7 days, 27.6% over 30 days and 9.3% year to date, but a 29.5% decline over 1 year, a 50.5% decline over 3 years and a 68.8% decline over 5 years, which raises questions about how the market now views its potential and...